Loading
NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.
Flavin-containing quinone reductase that catalyses two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species. Regulates cellular redox state primarily through quinone detoxification.
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Amrubicin and NSC84167.
In plain words · NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.
NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.
Flavin-containing quinone reductase that catalyses two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors.
No product in this corpus aims at NQO1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA NQO1: RNA tissue enhanced (stomach 1 493 nTPM); high antibody staining in 4 normal tissues; highest cancer staining pancreatic cancer (6 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Pancreatic ductal adenocarcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas NQO1 tissue; Open Targets ENSG00000181019 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Jaiswal A.K. et al, J. Biol. Chem, 1988, "Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16". Source.
Sources: HGNC HGNC:2874 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15559 (protein name, function text, keywords and locations (REST API)); CIViC gene NQO1 (3 evidence items, 0 assertions, 3 variants; diseases: Lung Cancer, Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0))
Flavin-containing quinone reductase that catalyses two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species. Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion. Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential. Location: Cytoplasm, cytosol (UniProt). Locus 16q22.1 (HGNC).
RNA: tissue enhanced (stomach 1 493 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Cerebellum, Cervix, Duodenum.
Medium only: head and neck cancer, prostate cancer, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"NQO1" OR ABSTRACT:"NQO1" OR TITLE:"NAD P H quinone dehydrogenase 1" OR ABSTRACT:"NAD P H quinone dehydrogenase 1" OR TITLE:"NAD P H dehydrogenase [quinone] 1" OR ABSTRACT:"NAD P H dehydrogenase [quinone] 1" OR TITLE:"QR1" OR ABSTRACT:"QR1" OR TITLE:"NMOR1" OR ABSTRACT:"NMOR1" OR TITLE:"DIA4" OR ABSTRACT:"DIA4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NQO1, not a curated reading list.
Shares KEAP1-NRF2 antioxidant pathway, CIViC, Lung cancer (all types).
Shares KEAP1-NRF2 antioxidant pathway, CIViC, Lung cancer (all types).
Shares KEAP1-NRF2 antioxidant pathway, CIViC, Lung cancer (all types), Pancreatic ductal adenocarcinoma.
Shares KEAP1-NRF2 antioxidant pathway, Pancreatic ductal adenocarcinoma.